Future oncology (London, England) · 2024
An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study).
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abe Yu, Kubonishi Shiro, Ri Masaki, Iino Masaki, Sunami Kazutaka, Ito Tomoki, Fukaya Masafumi, Kitano Toshiyuki, Ikeda Sho, Ota Shuichi, Kuroi Taiga, Iriyama Noriyoshi, Jo Tatsuro, Adachi Masaaki, Akahane Daigo, Kai Tatsuyuki, Kohara Yoichi, Kadowaki Norimitsu, Katayama Teruaki
Аннотация
Background: The ARROW study demonstrated that once-weekly carfilzomib and dexamethasone (wKd) therapy significantly prolonged progression-free survival compared with twice-weekly carfilzomib and dexamethasone therapy in relapsed or refractory multiple myeloma patients. Aim: To describe the treatment patterns, effectiveness and safety of wKd therapy in real-world settings in Japan. Methods: We investigated data from the medical records of 126 Japanese patients with relapsed or refractory multiple myeloma. Results: The overall response rate was 66.3%. The median progression-free survival was 9.5 months. The incidence of treatment-emergent adverse events of any grade and grade ≥3 were 45.8 and 20.8%, respectively. Conclusion: There were no new or unexpected safety signals in this study. This study demonstrated the effectiveness and safety profiles of wKd therapy in Japan.